Savant Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Savant Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-692	Closed	-$210K	–	1511
2025 Q4	$210K	Buy	+692	New	+$216K	﹤0.01%	1270

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Savant Capital's BIO Position: Q1 2026 in Review

Savant Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 692 shares — an estimated $210K sold.

Savant Capital first reported a position in BIO in Q4 2025 and held it in 1 quarter. The position peaked at $210K in Q4 2025. 396 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

Savant Capital reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
Savant Capital sold 692 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $210K.
Savant Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2025 and held it in 1 quarter.
Savant Capital's Bio-Rad Laboratories Class A position peaked at $210K in Q4 2025.
396 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Savant Capital's 13F filing for Q1 2026, filed 4 May 2026.